hotspot -WSS

hotspot

author：leisure time 2025-10-02 20:06:33 - browse：41

Pfizer on Friday said it was stopping development of a twice-daily oral obesity medication after an underwhelming clinical trial, a blow to the company’s efforts to compete in the booming field of weight-loss medications.

The medicine, danuglipron, met its primary target in a placebo-controlled Phase 2b trial, leading to a statistically significant amount of weight lost, the company said. But the weight reductions were smaller than those seen in trials of rival medicines targeting the same GLP-1 pathway, and a high rate of patients experienced side effects and dropped out of the trial.

Pfizer said it would not move twice-daily danuglipron into Phase 3 trials, but that instead it would focus on a once-daily formulation, which is currently undergoing pharmacokinetic studies. Data are expected in the first half of 2024.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies
Next article： Why the quest to eradicate polio has stumbled

focus

hotspot

WSS

'A game

Newly revealed memo details efforts to keep Trump in power following election loss

Eli Lilly CEO gives to Mike Pence presidential super PAC

Who are the detained American citizens released from prison in Iran?

Transgender sports debate: Physicians say bans are health issue

Listen: Your guide to Wegovy's blockbuster heart study

knowledge

hotspot

explore

Medical leaders decry Supreme Court decision on affirmative action

FDA weighs limits of animal data in assessing artificial wombs

Novavax promises a turnaround & Lilly roils the obesity market

Chamber of Commerce, DOJ clash in court over drug prices

Supreme Court strikes down use of affirmative action

White House drug shortages task force keeps mum with Congress

How one medical school became remarkably diverse

Timeline: Special counsel's investigation into Trump's handling of classified documents

Jerome Adams on the need for new antivirals for Covid

Newly revealed memo details efforts to keep Trump in power following election loss

explore

'A game

TB outbreak tied to bone grafts underscores testing shortcomings

Faced with fears of OxyContin misuse, sales reps touted its safety

White House Covid adviser calls on docs to combat misinformation

People with substance use disorder deserve online privacy

Covid's long

focus

hotspot

focus

hotspot